MX2021004213A - Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado. - Google Patents
Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado.Info
- Publication number
- MX2021004213A MX2021004213A MX2021004213A MX2021004213A MX2021004213A MX 2021004213 A MX2021004213 A MX 2021004213A MX 2021004213 A MX2021004213 A MX 2021004213A MX 2021004213 A MX2021004213 A MX 2021004213A MX 2021004213 A MX2021004213 A MX 2021004213A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- generation
- treatment
- replacement therapy
- gene replacement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744944P | 2018-10-12 | 2018-10-12 | |
| PCT/US2019/055917 WO2020077250A1 (en) | 2018-10-12 | 2019-10-11 | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004213A true MX2021004213A (es) | 2021-07-16 |
Family
ID=68426839
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004213A MX2021004213A (es) | 2018-10-12 | 2019-10-11 | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado. |
| MX2025013445A MX2025013445A (es) | 2018-10-12 | 2021-04-12 | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025013445A MX2025013445A (es) | 2018-10-12 | 2021-04-12 | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210348135A1 (https=) |
| EP (2) | EP3863662A1 (https=) |
| JP (2) | JP2022504740A (https=) |
| KR (1) | KR20210076051A (https=) |
| CN (2) | CN120349985A (https=) |
| AR (1) | AR116700A1 (https=) |
| AU (2) | AU2019357039B2 (https=) |
| BR (1) | BR112021006796A2 (https=) |
| CA (1) | CA3116283A1 (https=) |
| CO (1) | CO2021006060A2 (https=) |
| IL (1) | IL282140A (https=) |
| MX (2) | MX2021004213A (https=) |
| PH (1) | PH12021550794A1 (https=) |
| SG (1) | SG11202103614RA (https=) |
| TW (1) | TW202035439A (https=) |
| WO (1) | WO2020077250A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| US11939601B2 (en) | 2017-11-22 | 2024-03-26 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| TW202140791A (zh) * | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| AU2021261359A1 (en) * | 2020-04-21 | 2022-12-08 | Allen Institute | Artificial expression constructs for selectively modulating gene expression in neocortical layer 5 glutamatergic neurons |
| JP2023524577A (ja) * | 2020-05-05 | 2023-06-12 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 改変アデノ随伴ウイルス５カプシドおよびその使用 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| EP4158005A1 (en) * | 2020-06-01 | 2023-04-05 | ModernaTX, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| MX2023003805A (es) | 2020-10-01 | 2023-04-12 | Genzyme Corp | Casete de expresion de pah humana para el tratamiento de la pku mediante terapia de reemplazo genico dirigida al higado. |
| AU2022332276A1 (en) * | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| CN115572730A (zh) * | 2022-04-24 | 2023-01-06 | 复旦大学附属中山医院 | 一种gtf2h4高表达的内皮细胞系 |
| CN115772503B (zh) * | 2022-08-16 | 2023-10-17 | 广东省南山医药创新研究院 | 一种表达pah的基因修饰细胞药物及其制备方法与应用 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| CN117899238A (zh) * | 2023-12-07 | 2024-04-19 | 哈尔滨工业大学 | Pglyrp2基因的用途及其相关药物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DE69918090T2 (de) * | 1998-04-24 | 2005-06-16 | University Of Florida, Gainesville | Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| ATE437221T1 (de) * | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| US7261544B2 (en) | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US8440182B2 (en) * | 2007-05-24 | 2013-05-14 | The Board Of Regents Of The University Of Texas System | Methods and compositions for treating phenylketonuria |
| WO2010124180A1 (en) * | 2009-04-23 | 2010-10-28 | Phasebio Pharmaceuticals, Inc. | Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria |
| KR20180000341A (ko) | 2009-06-16 | 2018-01-02 | 젠자임 코포레이션 | 재조합 ａａｖ 벡터에 대한 개선된 정제 방법 |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| TR201908020T4 (tr) | 2011-02-17 | 2019-06-21 | Univ Pennsylvania | Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler. |
| CA2836921C (en) * | 2011-06-07 | 2020-08-18 | Wisconsin Alumni Research Foundation | Hepatocyte based insulin gene therapy for diabetes |
| FR2978457A1 (fr) * | 2011-07-27 | 2013-02-01 | Univ Paris Diderot Paris 7 | Composes contenant un vecteur viral a specificite hepatique et presentant une activite anti-inflammatoire |
| EP3044231B1 (en) * | 2013-09-12 | 2020-08-05 | BioMarin Pharmaceutical Inc. | Aav vectors comprising a gene encoding factor viii |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| WO2016037931A1 (en) * | 2014-09-11 | 2016-03-17 | Fundación Para La Investigación Médica Aplicada | Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases |
| CR20170406A (es) * | 2015-02-10 | 2017-11-14 | Genzyme Corp | Arni variante |
| TWI707951B (zh) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| EP3283126B1 (en) * | 2015-04-16 | 2019-11-06 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| MX2018012537A (es) * | 2016-04-15 | 2019-02-25 | Univ Pennsylvania | Terapia de genes para tratar hemofilia a. |
| EP3293260A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| MX2019006803A (es) * | 2016-12-13 | 2019-11-18 | Am Sciences Inc | Composicion farmaceutica para prevenir o tratar la hepatitis b. |
| KR102738752B1 (ko) * | 2016-12-30 | 2024-12-06 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 페닐케톤뇨증을 치료하기 위한 유전자 치료 |
| WO2019028273A1 (en) * | 2017-08-02 | 2019-02-07 | Dna2.0, Inc. Dba Atum | DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS |
| MX2023003805A (es) * | 2020-10-01 | 2023-04-12 | Genzyme Corp | Casete de expresion de pah humana para el tratamiento de la pku mediante terapia de reemplazo genico dirigida al higado. |
-
2019
- 2019-10-11 AU AU2019357039A patent/AU2019357039B2/en active Active
- 2019-10-11 KR KR1020217013976A patent/KR20210076051A/ko active Pending
- 2019-10-11 EP EP19797895.0A patent/EP3863662A1/en not_active Withdrawn
- 2019-10-11 US US17/283,433 patent/US20210348135A1/en active Pending
- 2019-10-11 CN CN202510330069.9A patent/CN120349985A/zh active Pending
- 2019-10-11 EP EP24200416.6A patent/EP4461814A3/en active Pending
- 2019-10-11 JP JP2021519879A patent/JP2022504740A/ja active Pending
- 2019-10-11 BR BR112021006796-5A patent/BR112021006796A2/pt unknown
- 2019-10-11 CA CA3116283A patent/CA3116283A1/en active Pending
- 2019-10-11 WO PCT/US2019/055917 patent/WO2020077250A1/en not_active Ceased
- 2019-10-11 MX MX2021004213A patent/MX2021004213A/es unknown
- 2019-10-11 CN CN201980082127.3A patent/CN113194982B/zh active Active
- 2019-10-11 SG SG11202103614RA patent/SG11202103614RA/en unknown
- 2019-10-14 TW TW108136919A patent/TW202035439A/zh unknown
- 2019-10-15 AR ARP190102921A patent/AR116700A1/es unknown
-
2021
- 2021-04-07 IL IL282140A patent/IL282140A/en unknown
- 2021-04-11 PH PH12021550794A patent/PH12021550794A1/en unknown
- 2021-04-12 MX MX2025013445A patent/MX2025013445A/es unknown
- 2021-05-10 CO CONC2021/0006060A patent/CO2021006060A2/es unknown
-
2024
- 2024-06-19 JP JP2024098655A patent/JP2024123125A/ja active Pending
-
2025
- 2025-09-25 AU AU2025237999A patent/AU2025237999A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021006796A2 (pt) | 2021-07-20 |
| AU2019357039A1 (en) | 2021-06-03 |
| CN120349985A (zh) | 2025-07-22 |
| CN113194982B (zh) | 2025-04-01 |
| MX2025013445A (es) | 2025-12-01 |
| KR20210076051A (ko) | 2021-06-23 |
| AU2025237999A1 (en) | 2025-10-23 |
| EP4461814A2 (en) | 2024-11-13 |
| TW202035439A (zh) | 2020-10-01 |
| JP2022504740A (ja) | 2022-01-13 |
| SG11202103614RA (en) | 2021-05-28 |
| PH12021550794A1 (en) | 2021-12-13 |
| CA3116283A1 (en) | 2020-04-16 |
| CN113194982A (zh) | 2021-07-30 |
| EP3863662A1 (en) | 2021-08-18 |
| EP4461814A3 (en) | 2025-02-26 |
| AU2019357039B2 (en) | 2025-10-09 |
| JP2024123125A (ja) | 2024-09-10 |
| IL282140A (en) | 2021-05-31 |
| AR116700A1 (es) | 2021-06-02 |
| WO2020077250A1 (en) | 2020-04-16 |
| CO2021006060A2 (es) | 2021-05-20 |
| US20210348135A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004213A (es) | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado. | |
| SA519402566B1 (ar) | تركيبات نافعة في معالجة ضمور العضل النخاعي | |
| CL2021002680A1 (es) | Deleción mediada por vector aav de punto activo mutacional grande para el tratamiento de distrofia muscular de duchenne | |
| SA521421559B1 (ar) | أجهزة قابلة للزرع للعلاج بالخلايا وطرق ذات الصلة | |
| MX2019007876A (es) | Terapia genetica para tratar fenilcetonuria. | |
| SA518400233B1 (ar) | علاج جيني لعلاج نزف الدم الوراثي a | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| CL2023000629A1 (es) | Partículas virales modificadas y usos de estas | |
| EA201691891A1 (ru) | Генная терапия для лечения пигментного ретинита | |
| GB2573664A (en) | Viral methods of T cell therapy | |
| CO2020003187A2 (es) | Rnai variante | |
| IL286283A (en) | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics | |
| CO2021008877A2 (es) | Uso de vectores lentivirales que expresan el factor ix | |
| ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| WO2020097369A8 (en) | Compositions and methods of inducing differentiation of a hair cell | |
| CO2023003418A2 (es) | Casete de expresión de pah humana para el tratamiento de la pku mediante terapia de reemplazo génico dirigida al hígado | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| PY1985273A (es) | Generación de pah humana mejorada para el tratamiento de pku severo por terapia de reemplazo genético dirigido | |
| MX2021004154A (es) | Transgen de codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 3 (pfic3). | |
| MX421742B (es) | Composiciones y métodos para usarse en terapia génica empleando plásmidos, vectores y vectores no virales que contienen pcbp1 y/o mutantes de pcbp1 útiles para el tratamiento de enfermedades hiperproliferativas | |
| CO2024016901A2 (es) | Métodos de tratamiento de la leucodistrofia metacromática | |
| CO2024004573A2 (es) | Terapia génica con frataxina | |
| EA202190249A1 (ru) | Пептидные соединения и их терапевтическое применение | |
| AR115858A1 (es) | Tratamiento de mucopolisacaridosis iva | |
| AR120249A1 (es) | Vectores virales adeno-asociados para el tratamiento de la enfermedad de niemann-pick tipo c |